You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ovarian Clear Cell Carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Clear Cell Carcinoma Trial in Houston (Dostarlimab, LB-100)

Not yet recruiting
  • Ovarian Clear Cell Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Sep 26, 2023

Ovarian Clear Cell Carcinoma Trial (Zimberelimab, Metformin Hydrochloride)

Not yet recruiting
  • Ovarian Clear Cell Carcinoma
  • (no location specified)
Feb 25, 2023

Ovarian Clear Cell Carcinoma Trial (Camrelizumab)

Not yet recruiting
  • Ovarian Clear Cell Carcinoma
  • (no location specified)
Oct 29, 2022

Ovarian Clear Cell Carcinoma, Gynecologic Cancer Trial in Boston (Lenvatinib, Pembrolizumab)

Recruiting
  • Ovarian Clear Cell Carcinoma
  • Gynecologic Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Oct 13, 2022

Ovarian Clear Cell Carcinoma Trial in Wuhan (Sintilimab, Bevacizumab Biosimilar IBI305)

Recruiting
  • Ovarian Clear Cell Carcinoma
  • Wuhan, Hubei, China
    Tongji Hospital of Tongji Medical College, Huazhong University o
Apr 18, 2022

Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma Trial (AMT-151)

Not yet recruiting
  • Advanced Solid Tumor
  • +18 more
  • (no location specified)
Aug 10, 2022

Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer Trial in New Haven (APG-5918)

Recruiting
  • Nasopharyngeal Carcinoma
  • +8 more
  • Springdale, Arkansas
    Highlands Oncology
Nov 11, 2022

Ovarian Tumors, Endometrial Tumors, Uterine Cervical Tumors Trial (Dostarlimab, Bevacizumab, Doxorubicin)

Not yet recruiting
  • Ovarian Neoplasms
  • +5 more
  • (no location specified)
Sep 3, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Chicago, Providence (Nivolumab, Ipilimumab)

Recruiting
  • Ovarian Cancer
  • +4 more
  • Chicago, Illinois
  • +3 more
Jan 26, 2023

Platinum-resistant Recurrent Clear Cell Ovarian Cancer Trial in Guangzhou (Niraparib, Anlotinib)

Not yet recruiting
  • Platinum-resistant Recurrent Clear Cell Ovarian Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nov 21, 2021

Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer Trial in Orlando, Albuquerque

Recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • olvimulogene nanivacirepvec
  • +3 more
  • Orlando, Florida
    AdventHealth Cancer Institute
Sep 1, 2022

Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma Trial in Rochester (Biopsy,

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +14 more
  • Biopsy
  • +6 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 28, 2023

Ovarian Cancer, Fallopian Tube Adenocarcinoma, Fallopian Tube Carcinosarcoma Trial in Seattle (Exercise Counseling, Aerobic

Terminated
  • Ovarian Cancer
  • +21 more
  • Exercise Counseling
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 6, 2022

Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Tumor Trial in Rochester

Active, not recruiting
  • Fallopian Tube Clear Cell Adenocarcinoma
  • +22 more
  • Laboratory Biomarker Analysis
  • Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
  • Rochester, Minnesota
    Mayo Clinic
Oct 7, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial (3 cycles chemo instead of 6 cycles chemo, 6 cycles

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • 3 cycles chemotherapy instead of 6 cycles chemotherapy
  • 6 cycles chemotherapy
  • (no location specified)
Jul 12, 2022

Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid

Not yet recruiting
  • Recurrent Endometrial Carcinoma
  • +8 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +7 more
  • (no location specified)
Jul 15, 2023

Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma Trial in United States (biological, other,

Recruiting
  • Cervical Adenocarcinoma
  • +47 more
  • Bevacizumab
  • +3 more
  • Phoenix, Arizona
  • +3 more
Dec 5, 2022

Small Cell Lung Cancer, Uveal Melanoma, Ovarian Clear Cell Carcinoma Trial in United States (PLX2853)

Completed
  • Small Cell Lung Cancer
  • +7 more
  • Scottsdale, Arizona
  • +4 more
Jul 20, 2022

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in

Recruiting
  • Fallopian Tube Carcinosarcoma
  • +28 more
  • Pegylated Liposomal Doxorubicin Hydrochloride
  • Peposertib
  • Aurora, Colorado
  • +7 more
Sep 2, 2022

Asian Multicenter Prospective Study of ctDNA Sequencing

Recruiting
  • Cervical Cancer
  • +5 more
  • NGS analysis of ctDNA
  • Tokyo, Japan
  • +18 more
Sep 28, 2022

Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Platinum-Resistant

Recruiting
  • Recurrent Fallopian Tube Clear Cell Adenocarcinoma
  • +5 more
  • Etigilimab
  • Nivolumab
  • Houston, Texas
    M D Anderson Cancer Center
Nov 22, 2021

Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or

Terminated
  • Ovarian Cancer
  • Ovarian Neoplasms
  • 18F-EF5 PET/CT scan
  • Optional biopsy
  • Vancouver, British Columbia, Canada
    BC Cancer Agency - Vancouver Centre
Feb 2, 2022

Fallopian Tube Carcinosarcoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial in Buffalo

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +10 more
  • Bevacizumab
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 29, 2022

Ovarian Cancer, Recurrent Cancer Trial (CYH33)

Not yet recruiting
  • Ovarian Cancer
  • Recurrent Cancer
  • (no location specified)
Sep 5, 2021